Tyra biosciences announces poster presentations at 2025 asco gastrointestinal cancers symposium

Carlsbad, calif. , jan. 22, 2025 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, announced today that two abstracts were accepted for presentation at the 2025 asco gastrointestinal cancers symposium (asco gi), taking place january 23-25, 2025, in san francisco, ca.
TYRA Ratings Summary
TYRA Quant Ranking